hero image
Cliff Bailey - Aston University. Birmingham, , GB

Cliff Bailey

Emeritus Professor, College of Health and Life Sciences | Aston University


Professor Bailey's research is mainly directed towards the pathogenesis and treatment of diabetes.






Professor Clifford Bailey, University of Aston, UK, on the updated EURADIA DIAMAP diabetes project Professor Cliff Bailey - The diabetes therapy pipeline: what can we expect next?




Professor Bailey, PhD, FRCP(Edin), FRCPath is professor of clinical science in Life and Health Sciences at Aston University in Birmingham, UK, and fellow of both the Royal College of Physicians of Edinburgh of the Royal College of Pathologists.

He currently serves as senior editor of Diabetes and Vascuar Disease Research and has held editorial positions with the British Journal of Pharmacology; Diabetes, Obesity, and Metabolism; Lancet Diabetes Endocrinol, and Primary Care Diabetes. over the years.

He has been a Royal Society vising scientist at the University of Sourth Calironia in Los Angeles as well as a visiting scientist at Hanover Medical School in Germany.

He is also director of Biomedical Sciences Research in the Nutritional Biomedicine Research Group and a member of the research team in the Diabetes Research Group in the Aston University Research Centre for Healthy Ageing at Aston University.

He has published more than 400 research papers and reviews, as well as four textbooks, and has been honored with numerous awards including the Lunar Society Medal, the Banting Memorial Lecturer by the Diabetes UK, and the Royal Society of Biology Charter Lecturer.

Areas of Expertise (5)



Insulin Therapy

Diabetes Treatments

Surrogate Beta-Cells

Accomplishments (11)

Aston University Anniversary Chair


Royal Society of Biology Charter Lecturer


Banting Memorial Lecturer


Elsie Bertram Memorial Lecture, University of East Anglia


Lunar Society Medal


American Diabetes Association, State-of-the-Art Lecturer


Fernandez-Cruz XXVII Memorial Symposium Lecturer


St. Andrew’s Symposium Lecture, Royal College of Physicians, Edinburgh


Howard Kolodny Lecture, Albert Einstein College of Medicine, New York


Citations in Who’s Who in Science (USA), Who’s Who in Medicine (USA)


Ciba Lecture prize in Clinical Biochemistry


Affiliations (9)

  • British Endocrine Society
  • British Pharmacological Society
  • Diabetes UK, Medical and Scientific Section
  • Diabetes UK, Medical and Scientific Section
  • European Association for the Study of Diabetes
  • Founding Member of EASD Islet Study Group
  • International Society of Diabetes & Vascular Disease
  • Royal College of Pathologists
  • Royal College of Physicians, Edinburg

Media Appearances (2)

Aston University professor named world expert in type 2 diabetes mellitus

Aston University News  online


Aston University professor emeritus, Cliff Bailey has been named as a world expert in type 2 diabetes mellitus by Expertscape, based on his research publications over the last ten years.

view more

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

BusinessWire  online


Professor Clifford J Bailey Professor of Clinical Science, Life and Health Sciences University of Aston, UK

view more

Articles (3)

864-P: Glycemic Control across eGFR Categories with the Dual SGLT1 and 2 Inhibitor Sotagliflozin in SCORED


2022 In cardiovascular (CV) outcome trials (OT) of glucose-lowering medications (GLM) , glycated hemoglobin (A1c) is typically treated according to local standard of care, with aim of glycemic equipoise between the randomized groups. However, in SGLT inhibitor CVOTs, larger A1c reductions are consistently seen in the active therapy vs. placebo (PBO) groups, since the former has access to an additional class of GLM. SCORED was a multicenter, double-blind, placebo-controlled CVOT of the dual SGLT1 and 2 inhibitor sotagliflozin (SOTA) , which may have preserved antihyperglycemic effects even in those with advanced chronic kidney disease (CKD.) We assessed the association between A1c lowering and assignment to SOTA vs. PBO in the overall trial population and across various pre-specified subgroups, including CKD categories. 10,584 type 2 diabetes (T2D) (A1c ≥7%) patients with CKD (eGFR 25-60 mL/min/1.73 m2) and increased CV risk were randomized to SOTA vs. PBO and followed for a median of 15.9 months.

view more

Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin

Frontiers in Pharmacology

2022 Objectives: Pre-existing or new diabetes confers an adverse prognosis in people with Covid-19. We reviewed the clinical literature on clinical outcomes in metformin-treated subjects presenting with Covid-19. Methods: Structured PubMed search: metformin AND [covid (ti) OR covid-19 (ti) OR covid19 (ti) OR coronavirus (ti) OR SARS-Cov2 (ti)], supplemented with another PubMed search: “diabetes AND [covid OR covid-19 OR covid19 OR coronavirus (i) OR SARS-Cov2 (ti)]” (limited to “Clinical Study”, “Clinical Trial”, “Controlled Clinical Trial”, “Meta-Analysis”, “Observational Study”, “Randomized Controlled Trial”, “Systematic Review”). Results: The effects of metformin on the clinical course of Covid-19 were evaluated in retrospective analyses: most noted improved clinical outcomes amongst type 2 diabetes patients treated with metformin at the time of hospitalisation with Covid-19 infection.

Metformin and the heart: Update on mechanisms of cardiovascular protection with special reference to comorbid type 2 diabetes and heart failure

Metabolism: Clinical and Experimental

2022 Metformin has been in clinical use for the management of type 2 diabetes for more than 60 years and is supported by a vast database of clinical experience: this includes evidence for cardioprotection from randomised trials and real-world studies. Recently, the position of metformin as first choice glucose-lowering agent has been supplanted to some extent by the emergence of newer classes of antidiabetic therapy, namely the sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. These agents have benefitted through support from large cardiovascular outcomes trials with more modern trial designs than earlier studies conducted to assess metformin. Nevertheless, clinical research on metformin continues to further assess its many potentially advantageous effects. Here, we review the evidence for improved cardiovascular outcomes with metformin in the context of the current era of diabetes outcomes trials. Focus is directed towards the potentially cardioprotective actions of metformin in patients with type 2 diabetes and heart failure (HF), now recognised as the most common complication of diabetes.

view more